Cancer Drugs in the United States: Justum Pretium—The Just Price
Reads0
Chats0
TLDR
In the context of cancer therapy, the prices of new anticancer agents seem to be decided by pharmaceutical companies according to what the market will bear as discussed by the authors, and there is little correlation between the actual efficacy of a new drug and its price, as measured by cost-efficacy (CE) ratios, prolongation of patient life in years, or quality-adjusted life-years (QALYs)Abstract:
In 2011, health care spending in the United States was estimated at $27 trillion,1 making it the sixth largest economy in the world, larger than the national budget of France National health care spending is approximately 18% of the US gross domestic product, more than $8,000 per person, compared with 6% to 9% in Europe and elsewhere, with apparently similar patient outcomes Total Medicare expenditures in 2011 were $549 billion2 A study comparing the Canadian universal health care program in older patients with the Medicare program in the United States suggested that adopting more-prudent health care strategies could have saved $256 trillion from 1980 to 2009, or approximately one fifth of our national debt, without compromising benefit3
In the debate about health care and Medicare solvency, strategies that reduce health care costs without compromising treatment efficacy and patient safety should be explored Several experts have addressed health care costs in excellent analyses and editorials,4–9 but their efforts have not translated into concrete decisions and results that benefit patients, providers, insurers, or payees However, an interesting exception occurred recently when Bach et al,10 in a New York Times editorial, compared the efficacy and cost of two anticancer agents—ziv-aflibercept (Zaltrap; sanofi-aventis, Bridgewater, NJ) and bevacizumab (Avastin; Genentech, South San Francisco, CA)—in the treatment of metastatic colorectal cancer After noting ziv-aflibercept had similar efficacy but was twice the cost of bevacizumab, they stated it would be excluded from their hospital formulary10 Within 1 week, sanofi-aventis, the company producing ziv-aflibercept, reduced its price by 50% Thus, expert review of anticancer therapies for their cost-benefit ratios may influence institutional usage and drug pricing while preserving a healthy profit margin for pharmaceutical companies
Aristotle is credited to be the first to discuss the relationship between price and worth in his book Justum Pretium—the just price Sixteen centuries later, Saint Albert the Great and Saint Thomas Aquinas refined Aristotle's argument Their conclusion: of moral necessity, price must reflect worth In the context of cancer therapy, the prices of new anticancer agents seem to be decided by pharmaceutical companies according to what the market will bear There is little correlation between the actual efficacy of a new drug and its price, as measured by cost-efficacy (CE) ratios, prolongation of patient life in years, or quality-adjusted life-years (QALYs)7 Compared with a decade ago, the price range of new anticancer agents has more than doubled, from $4,500 to more than $10,000 per month4,5 Of the 12 anticancer drugs approved by the US Food and Drug Administration (FDA) in 2012, only three prolonged survival, two of them by less than 2 months Yet nine were priced at more than $10,000 per month Many so-called targeted therapies have been priced between $6,000 to 12,000 per month, or approximately $70,000 to 115,000 per patient annually (Table 1)11 However, novel or reformulated chemotherapy drugs like pralatrexate (Folotyn; Allos Therapeutics, Westminster, CO; $120,000 per course), omacetaxine (Synribo; Teva Pharmaceuticals, North Wales, PA; $28,000 for induction, $14,000 for monthly treatments), and pegylated asparaginase (Oncaspar; Sigma-Tau Pharmaceuticals, Gaithersburg, MD; $22,000 per course) are also expensive Hillner and Smith7 suggested that profiteering (ie, making profit by unethical methods, such as raising prices after natural disasters) could be applied to this recent trend, where a life-threatening disease is the natural disaster
Table 1
Cost of Targeted Therapy
Pharmaceutical companies justify the high price of drugs as necessary to support investment in research and development The often-cited cost of bringing anticancer drugs to FDA approval is $1 billion12 This figure is roughly calculated by dividing total expenditures on research and development by the number of agents that receive FDA approval However, this figure may be inflated, because it includes ancillary expenses, salaries, bonuses, and other indirect costs not related to research or development13 as well as an 11% compounded discount rate over 10 years based on stock market returns on capital investment14 Other independent estimates of cost of drug development put the figure as low as 4% to 25% of this estimate15–17
Allowing the producer-dominated market to set drug prices has spiraled the cost of cancer drugs out of control In this analysis, we highlight examples of the cost benefit of different anticancer agents and suggest scenarios for reduced drug pricing, while preserving the profit-making incentive, by linking price to a true measure of quality: preservation and meaningful prolongation of liferead more
Citations
More filters
Journal ArticleDOI
Annual Report to the Nation on the Status of Cancer, 1975-2014, Featuring Survival.
Ahmedin Jemal,Elizabeth Ward,Christopher J. Johnson,Kathleen A. Cronin,Jiemin Ma,A. Blythe Ryerson,Angela B. Mariotto,Andrew J. Lake,Reda J. Wilson,Recinda L. Sherman,Robert N. Anderson,S. Jane Henley,Betsy A. Kohler,Lynne Penberthy,Eric J. Feuer,Hannah K. Weir +15 more
TL;DR: Progress in reducing death rates and improving survival is limited for several cancer types, underscoring the need for intensified efforts to discover new strategies for prevention, early detection, and treatment and to apply proven preventive measures broadly and equitably.
Journal ArticleDOI
The ErbB/HER family of protein-tyrosine kinases and cancer.
TL;DR: Several malignancies are associated with the mutation or increased expression of members of the ErbB family including lung, breast, stomach, colorectal, head and neck, and pancreatic carcinomas and glioblastoma
Journal ArticleDOI
Gut microbiota modulation of chemotherapy efficacy and toxicity
James L. Alexander,James L. Alexander,Ian D. Wilson,Julian Teare,Julian R. Marchesi,Jeremy K. Nicholson,James Kinross,James Kinross +7 more
TL;DR: The implications of pharmacomicrobiomics in cancer therapeutics are outlined and how the microbiota might be modified in clinical practice to improve efficacy and reduce the toxic burden of these compounds are defined.
Journal ArticleDOI
Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13
Courtney Davis,Huseyin Naci,Evrim Gurpinar,Elita Poplavska,Ashlyn Pinto,Ajay Aggarwal,Ajay Aggarwal +6 more
TL;DR: This systematic evaluation of oncology approvals by the EMA in 2009-13 shows that most drugs entered the market without evidence of benefit on survival or quality of life.
Journal ArticleDOI
Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update.
TL;DR: This review presents the physicochemical properties of all of the FDA-approved small molecule protein kinase inhibitors.
References
More filters
Journal ArticleDOI
Survival trends among patients with advanced renal cell carcinoma (RCC) in the United States.
TL;DR: This population based study showed that there was no significant improvement in relative survival rates among advanced RCC patients in the era of targeted agents.
Posted Content
The Savings from an Efficient Medicare Drug Plan
TL;DR: This report projects the savings from a drug benefit program that was designed with efficiency in mind, and concludes that the Medicare Modernization Act should be amended to address these challenges.
Related Papers (5)
The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts
Camille N. Abboud,Ellin Berman,Adam D. Cohen,Jorge E. Cortes,Daniel J. DeAngelo,Michael W. Deininger,Steven M. Devine,Brian J. Druker,Amir T. Fathi,Elias Jabbour,Madan Jagasia,Hagop M. Kantarjian,Jean Khoury,Pierre Laneuville,Richard A. Larson,Jeffrey H. Lipton,Joseph O. Moore,Tariq I. Mughal,Susan O'Brien,Javier Pinilla-Ibarz,Alfonso Quintás-Cardama,Jerald P. Radich,Vishnu Reddy,Charles A. Schiffer,Neil P. Shah,Paul J. Shami,Richard T. Silver,David S. Snyder,Richard Stone,Moshe Talpaz,Ayalew Tefferi,Richard A. Van Etten,Meir Wetzler,Elisabetta Abruzzese,Jane F. Apperley,Massimo Breccia,Jenny Byrne,Francisco Cervantes,Ekaterina Chelysheva,Richard E. Clark,Hugues de Lavallade,Iryna Dyagil,Carlo Gambacorti-Passerini,John M. Goldman,Ibrahim C. Haznedaroglu,Henrik Hjorth-Hansen,Tessa L. Holyoake,Brian J. P. Huntly,Philipp le Coutre,Elza Lomaia,Francois-Xavier Mahon,David Marin-Costa,Giovanni Martinelli,Jiri Mayer,Dragana Milojkovic,Eduardo Olavarria,Kimmo Porkka,Johan Richter,Philippe Rousselot,Giuseppe Saglio,Güray Saydam,Jesper Stentoft,Anna G. Turkina,Paolo Vigneri,Andrey Zaritskey,Alvaro Aguayo,Manuel Ayala,Israel Bendit,Raquel Bengió,Carlos Best,Eduardo Bullorsky,Eduardo Cervera,Carmino DeSouza,Ernesto Fanilla,David Gómez-Almaguer,Nelson Hamerschlak,José A. López,Alicia Magarinos,Luis Meillon,Jorge Milone,Beatriz Moiraghi,Ricardo Pasquini,Carolina Pavlovsky,Guillermo J. Ruiz-Argüelles,Nelson Spector,Christopher Arthur,Peter Browett,Andrew Grigg,Jianda Hu,Xiao-Jun Huang,Timothy P. Hughes,Qian Jiang,Saengsuree Jootar,Dong-Wook Kim,Hemant Malhotra,Pankaj Malhotra,Itaru Matsumura,Junia V. Melo,Kazunori Ohnishi,Ryuzo Ohno,Tapan Saikia,Anthony P. Schwarer,Naoto Takahashi,Constantine S. Tam,Tetsuzo Tauchi,Kensuke Usuki,Jianxiang Wang,Fawzi Abdel-Rahman,Mahmoud Aljurf,Ali Bazarbachi,Dina Ben Yehuda,Naeem Chaudhri,Muheez A. Durosinmi,Hossam Kamel,Vernon J. Louw,Bassam Francis Matti,Arnon Nagler,Pia Raanani,Ziad Salem +118 more
Delivering affordable cancer care in high-income countries
Richard Sullivan,Jeffrey Peppercorn,Karol Sikora,John Zalcberg,Neal J. Meropol,Eitan Amir,David Khayat,Peter Boyle,Philippe Autier,Ian F. Tannock,Tito Fojo,Jim Siderov,Steve Williamson,Silvia Camporesi,J. Gordon McVie,Arnie Purushotham,Peter Naredi,Alexander M.M. Eggermont,Murray F. Brennan,Michael L. Steinberg,Mark De Ridder,Susan A. McCloskey,Dirk Verellen,Terence Roberts,Guy Storme,Rodney J. Hicks,Peter J. Ell,Bradford R. Hirsch,David P. Carbone,Kevin A. Schulman,Paul Catchpole,David Taylor,Jan Geissler,Nancy G Brinker,David O. Meltzer,David J. Kerr,Matti Aapro +36 more
American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options
Lowell E. Schnipper,Nancy E. Davidson,Dana S. Wollins,Courtney Tyne,Douglas W. Blayney,Diane Blum,Adam P. Dicker,Patricia A. Ganz,J. Russell Hoverman,Robert M. Langdon,Gary H. Lyman,Neal J. Meropol,Therese M. Mulvey,Lee N. Newcomer,Jeffrey Peppercorn,Blase N. Polite,Derek Raghavan,Gregory Rossi,Leonard B. Saltz,Deborah Schrag,Thomas J. Smith,Peter Paul Yu,Clifford A. Hudis,Richard L. Schilsky +23 more